S&P DJI Announces March 2019 Quarterly Rebalance
Filed with ASX · · 6 pages · English
Earlier from Opthea
- Opthea Ph2b Trial Advances With 2nd Positive Safety Review
- Opthea Granted Japanese Patent Covering OPT-302
- Opthea Options Exercise Generates Proceeds of A$13.3m
- Opthea confirms final patient enrolment in Ph2b wAMD trial
- Opthea Phase 2b wAMD trial fully recruited ahead of schedule
Later from Opthea
- Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
- Opthea Provides Timing Update on OPT-302 Clinical Trials
- Opthea European Patent Application to be Granted
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
- Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea